• Pharmaxis Ltd., of Sydney, Australia, said a Phase II trial of Bronchitol in children with cystic fibrosis closed its enrollment phase after entering 25 subjects, fewer than the 42 originally expected. The number was revised following a review of the trial and because of a shortage of volunteers at the two UK sites. Children in the trial are completing three months of treatment with each of three different therapies - Bronchitol alone, both Bronchitol and Pulmozyme (domase alfa, Genentech Inc.), and Pulmozyme alone - and results will be assessed by changes in lung function, airway inflammation, infections and quality of life. The study is expected to conclude in 2008.